Global Surveillance of the In Vitro Activity of Micafungin against Candida: A Comparison with Caspofungin Using Clinical and Laboratory Standards Institute Recommended Methods.

M. A. PFALLER, L. BOYKEN, R. J. HOLLIS, J. KROEGER, S. A. MESSER, S. TENDOLKAR, D. J. DIEKEMA;

Author address: 

Univ. of Iowa Coll. of Med., Iowa City, IA.

Abstract: 

Background: Micafungin (MICA) is an echinocandin antifungal recently approved for the prevention and treatment of invasive fungal infection. Prospective sentinel surveillance for the emergence of in vitro resistance to MICA among invasive Candida spp. isolates is indicated. Methods: We determined the in vitro activity of MICA against 2,656 invasive (bloodstream or sterile site) unique patient isolates of Candida collected from 60 medical centers worldwide in 2004 and 2005. We performed antifungal susceptibility testing according to the Clinical and Laboratory Standards Institute (CLSI) M27-A2 method and used a 24-hour prominent inhibition endpoint for MIC determination. Caspofungin (CASP) was tested in parallel against all isolates. Results: Of 2,656 invasive Candida spp. isolates, species distribution was 56% C. albicans, 14% C. parapsilosis, 13% C. glabrata, 10% C. tropicalis, 2% C. krusei, 2% C. guilliermondii, 1% C. lusitaniae, 1% C. kefyr, and 1% other Candida species. Overall, MICA was very active against Candida (MIC50/MIC90, 0.015/1 µg/ml, 96% inhibited at MIC
2006

abstract No: 

M-1583

Full conference title: 

46th Interscience Conference on Antimicrobial Agents and Chemotherapy
    • ICAAC 46th